• 1
    Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13: 34551.
  • 2
    Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797806.
  • 3
    Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as predictor of further damage. Rheumatology (Oxford) 2004; 43: 34952.
  • 4
    Stoll T, Sutcliffe N, Klaghofer R, Isenberg DA. Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage? A prospective study. Ann Rheum Dis 2000; 59: 83235.
  • 5
    Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: Changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 26674.
  • 6
    Alarcon GS, Roseman JM, Bartolucci AA, Friedman AW, Moulds JM, Goel N, et al. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. Arthritis Rheum 1998; 41: 117380.
  • 7
    Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999; 8: 197209.
  • 8
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 9
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 10
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 80913.
  • 11
    Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998; 41: 116172.
  • 12
    US Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington (DC): Housing and Household Economic Statistics Division; 1995.
  • 13
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 14
    Aarden LA, De Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975; 254: 50515.
  • 15
    Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993; 20: 168493.
  • 16
    Harris EN. Special report. The second international anti-cardiolipin standardization workshop/the Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol 1990; 94: 47684.
  • 17
    Roisin JP, Contant G, Martinoli JL. Detection of lupus-like anticoagulants (LA). Use of hexagonal phosphatidylethanolamine and of an APTT reagent sensitive to LA. Thromb Haemost 1991; 65: 2023.
  • 18
    Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1995; 74: 118590.
  • 19
    Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998; 7: 6117.
  • 20
    Engle EW, Callahan LF, Pincus T, Hochberg MC. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitudes Index. Arthritis Rheum 1990; 33: 2816.
  • 21
    Cohen S, Mermelstein R, Kamarch T, Hoberman HN. Measuring the functional components of social support. In: SarasonIG, SarasonBR, editors. Social support: theory, research and applications. Boston: Martinus Nijhoff; 1985. p. 7394.
  • 22
    Pilowsky I. Dimensions of illness behavior as measured by the illness behavior questionnaire: a replication study. J Psychosom Res 1993; 37: 5362.
  • 23
    Alarcon GS, McGwin G Jr, Bastian HM, Fessler BJ, Baethge BA, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups. XIII. The “weighted” criteria as predictors of damage. Lupus 2002; 11: 32931.
  • 24
    Alarcon GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11: 95101.
  • 25
    Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998; 25: 6549.
  • 26
    Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 24854.
  • 27
    Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 936.
  • 28
    Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 15260.
  • 29
    Vila LM, Alarcon GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43: 35863.
  • 30
    Fessler BJ, McGwin G Jr, Roseman JM, Bastian HM, Friedman AW, Lisse JR, et al. Characteristics of ACR criteria accrual for systemic lupus erythematosus (SLE) in 3 ethnic groups [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S252.
  • 31
    Vila LM, Alarcon GS, McGwin G Jr, Baethge BA, Reveille JD. HLA-class II alleles among two distinct U. S. Hispanic populations with systemic lupus erythematosus [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S5745.
  • 32
    Reveille JD, Beasley TM, Tan FK, Roseman JM, Vila LM, Bastian HM, et al. Admixture as a measure of genomic control: data from a multiethnic lupus cohort [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S225.
  • 33
    Alarcon GS, Rodriguez JL, Benavides G, Brooks K, Kurusz H, Reveille JD. Systemic lupus erythematosus in three ethnic groups. V. Acculturation, health-related attitudes and behaviors and disease activity in Hispanic patients from the LUMINA cohort. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res 1999; 12: 26776.
  • 34
    Finch BK, Kolody B, Vega WA. Perceived discrimination and depression among Mexican-origin adults in California. J Health Soc Behav 2003; 41: 295313.
  • 35
    Escalante A, del Rincon I. Epidemiology and impact of rheumatic disorders in the United States Hispanic population. Curr Opin Rheumatol 2001; 13: 10410.
  • 36
    Callister LC, Birkhead A. Acculturation and perinatal outcomes in Mexican immigrant childbearing women: an integrative review. J Perinat Neonatal Nurs 2002; 16: 2238.
  • 37
    Finch BK, Vega WA. Acculturation stress, social support, and self-rated health among Latinos in California. J Immigr Health 2003; 5: 10917.
  • 38
    Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 71822.
  • 39
    Soares M, Reis L, Papi JA, Cardoso CR. Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients. Lupus 2003; 12: 78894.
  • 40
    Ho KT, Reveille JD, Baethge BA, Tan FK, Friedman AW, Roseman J, et al. The use of hydroxychloroquine in the prevention of thrombosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S375.
  • 41
    Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 1: S1622.
  • 42
    Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 9249.
  • 43
    Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 1913.
  • 44
    Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 18018.
  • 45
    Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 19559.